早期克罗恩病1年深度缓解可预防疾病进展
该研究基于CALM试验122例早期中重度克罗恩病患者的随访数据,分析深度缓解与疾病进展的关系。中位随访3.02年,34例(27.9%)发生主要不良结局。深度缓解者主要不良结局风险显著降低(调整HR 0.19,95%CI 0.07-0.31)。
要点
- 早期中重度克罗恩病诱导深度缓解可降低疾病进展风险
- 深度缓解定义为CDEIS评分低于4且无深溃疡或激素治疗至少8周
- 无论采用tight control还是传统管理策略,深度缓解的获益一致
核心结论
- 早期中重度克罗恩病患者诱导深度缓解与中位3年随访期内疾病进展风险降低相关。
研究设计与样本
- 基于CALM研究随访数据,纳入122例早期中重度克罗恩病患者(平均年龄31.2±11.3岁,中位病程0.2年,IQR 0.1-0.5),来自31个中心,占原CALM人群50%。
- 61例随机分配至tight control策略,61例分配至传统管理;随访中位3.02年(范围0.05-6.26年)。
主要发现
- 随访期间34例(27.9%)报告主要不良结局。
- 调整潜在混杂因素后,深度缓解与主要不良结局风险降低显著相关(调整HR 0.19,95%CI 0.07-0.31)。
关键数值与推荐
- 深度缓解定义为CDEIS评分低于4,且无深溃疡或激素治疗,持续至少8周。
- 主要结局为随访期间提示CD进展的复合终点:新发内瘘或脓肿、狭窄、肛周瘘或脓肿、因CD住院或手术。
临床怎么用
- 对早期中重度克罗恩病,应将诱导深度缓解作为治疗目标以降低疾病进展风险。
- 深度缓解的获益不依赖于tight control或传统管理策略,提示达标治疗的核心在于达到深度缓解本身。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We investigated the effects of inducing deep remission in patients with early Crohn's disease (CD). METHODS: We collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1-0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05-6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period. RESULTS: Major adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07-0.31) was significantly associated with a lower risk of major adverse outcome. CONCLUSIONS: In an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy.
引用
- Ungaro RC, Yzet C, Bossuyt P, et al. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology. 2020. PMID: 32224129. doi:10.1053/j.gastro.2020.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。